Literature DB >> 12894067

Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear.

Marc Heckmann1, Bianca Teichmann, Ulrike Schröder, Reiner Sprengelmeyer, Andrés O Ceballos-Baumann.   

Abstract

BACKGROUND: Individuals with intense frowning are commonly perceived as expressing negative emotions. Anger, fear, and sadness are associated with corrugator ("frown") muscle activity.
OBJECTIVE: We sought to study how faces were perceived by others after denervation of frown muscles with localized botulinum toxin injections for treatment of facial frown lines.
METHODS: Facial photographs were taken from volunteers before and after botulinum toxin injection. These photographs were shown to viewers who were naive to the procedure and asked to rate the expressed intensity of anger, sadness, fear, and happiness. As reference for this task we used a standard set of pictures of facial affect displaying different intensity levels for each emotion tested.
RESULTS: Of 40 viewers, 39 were able to discriminate different intensity levels (0%, 25%, 50%, 75%, and 100%) of emotional affect in the control task. According to their ratings faces with denervated frown muscle activity expressed relatively less anger (-40%), fear (-49%), sadness (-10%), and more happiness (+71%).
CONCLUSION: Frown muscle activity is essential for both negative and positive emotional expressions. Temporary denervation using botulinum toxin enhances the facial expression of positive emotion resulting in a shift rather than a loss of facial affect.

Mesh:

Substances:

Year:  2003        PMID: 12894067     DOI: 10.1067/s0190-9622(03)00909-5

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  [Lidocaine-containing hyaluronic acid filler on a CPM® basis for lip augmentation : Experience from clinical practice].

Authors:  T Fischer; G Sattler; G Gauglitz
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

Review 2.  Treatment of Depression with Botulinum Toxin.

Authors:  Marc Axel Wollmer; Michelle Magid; Tillmann H C Kruger; Eric Finzi
Journal:  Toxins (Basel)       Date:  2022-05-31       Impact factor: 5.075

3.  Botulinum toxin type a for the treatment of hyperkinetic lines of the face.

Authors:  Dinesh Singh Chauhan; K M Cariappa; Yadavalli Guruprasad
Journal:  J Maxillofac Oral Surg       Date:  2012-08-28

Review 4.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

5.  Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study.

Authors:  Elena Gubanova; May Haddad Tabet; Yvonne Bergerova; Olena Moiseieva; Andrey Chemeris; Elena Sanches; Alisa Sharova; Luisa Rodriguez Pose; Romain Raymond; Inna Prygova; Ian Carlisle
Journal:  Aesthetic Plast Surg       Date:  2018-08-17       Impact factor: 2.326

6.  Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Huan Qian; Fangjie Shao; Cameron Lenahan; Anwen Shao; Yingjun Li
Journal:  Front Psychiatry       Date:  2020-12-04       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.